Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistant disease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependent and refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistant active UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy; special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinical experience ofanationalworkinggroup.
Orlando, A., Armuzzi, A., Papi, C., Annese, V., Ardizzone, S., Biancone, L., et al. (2011). Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease. DIGESTIVE AND LIVER DISEASE, 43(43), 1-20.
Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease
COTTONE, Mario
2011-01-01
Abstract
Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistant disease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependent and refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistant active UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy; special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinical experience ofanationalworkinggroup.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Linee guida Biologici_DLD 2010.pdf
Solo gestori archvio
Dimensione
330.26 kB
Formato
Adobe PDF
|
330.26 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
